Lipid Insights

From Cholesterol to Dyslipidemia: Translating the 2026 Multi-Society Guideline into Clinical Practice | Month 2 Podcast

LDL-C alone doesn't tell the whole story, and the 2026 Multi-Society Dyslipidemia Guideline makes that clear. In the second installment of this four-part CME/CE-accredited series, host Kaye-Eileen Willard, MD, FNLA sits down with Jessica Peña, MD, FNLA and Ann Marie Navar, MD, PhD to dig into the biomarkers reshaping cardiovascular risk assessment: ApoB vs. LDL-C discordance, the role of Lp(a) in everyday practice, and how clinicians can effectively use CAC scoring to guide patient management.

This episode is a companion piece to the Month 2 webinar, “Risk Assessment in 2026: PREVENT, ApoB, Lp(a), and CAC.” We encourage you to check it out as the two were built to work together. WATCH WEBINAR

CME/CE Credit: This activity has been approved for AMA PRA Category 1 Credit and is eligible for ACPE, ANCC, and CDR credit. CME/CE credit is provided by the National Lipid Association. Claim your credit and complete the activity assessment at https://www.lipid.org/from-cholesterol-to-dyslipidemia-month-two/. Questions? Contact CME@lipid.org.

In honor of FH Awareness Day, this special Lipid Insights episode features a conversation with Jose Lopez, MS, recipient of the Donald Hunninghake, MD, Familial Hypercholesterolemia (FH) Abstract Award at the 2026 NLA Scientific Sessions.

Guest host and Foundation of the NLA President Ann Liebeskind, MD, FNLA, FAAP sits down with Jose to discuss his award-winning abstract, "Early Detection of Familial Hypercholesterolemia Through Point of Care Testing in 2-Year-Olds" — exploring the promise of point-of-care lipid testing in very young children as a practical strategy for identifying FH.

A timely and important listen for any clinician committed to closing the gap in FH detection. 
Watch the video version on YouTube HERE.

The 2026 Multi-Society Dyslipidemia Guideline introduced significant changes; but, this episode isn't just about what's new. It's about why the field decided a change was necessary in the first place. 
In the first installment of this four-part CME/CE-accredited series, host Dave Dixon, PharmD, CLS, FNLA sits down with NLA President Dinesh Kalra, MD, FNLA and Salim Virani, MD to unpack the foundational shift from cholesterol-focused care to a broader dyslipidemia paradigm. The conversation covers why atherogenic lipoprotein exposure earlier in life matters, the key clinical misconceptions embedded in the prior guideline, and what clinicians most commonly misunderstand about lipid risk.
This episode is a companion piece to the Month 1 webinar, From Cholesterol to Dyslipidemia: What Changed in the 2026 Guideline? We encourage you to check it out as the two were built to work together: https://youtu.be/9v4WBVfKsho. 
CME/CE Credit: This activity has been approved for AMA PRA Category 1 Credit and is eligible for ACPE, ANCC, and CDR credit. CME/CE credit is provided by the National Lipid Association. Claim your credit and complete the activity assessment at https://www.lipid.org/new-dyslipidemia-paradigm-month-one/. Questions? Contact CME@lipid.org.

Hot off the European Society of Cardiology Congress in Munich, this Lipid Insights episode takes a closer look at a significant announcement in triglyceride science and its implications for clinical practice. Host Peter H. Jones, MD, MNLA sits down with Christie M. Ballantyne, MD, MNLA to discuss the 12-month pivotal trial results from SHASTA-3 and SHASTA-4 — evaluating plozasiran in patients with severe hypertriglyceridemia. If you missed Munich, this is your catch-up.
Watch the video version on YouTube HERE.

Familial chylomicronemia syndrome (FCS) is one of the rarest and most challenging lipid disorders to manage, but the landscape is changing rapidly. In this Industry Innovations episode, guest host Kevin Maki, PhD, CLS, MNLA sits down with Archna Bajaj, MD, FNLA for a comprehensive and forward-looking conversation on FCS from every angle.
Dr. Bajaj walks through the realities of living with FCS — from diagnosis to the demands of a strict ultra-low-fat diet — before turning to what has the field buzzing: two landmark APOC3-targeting therapies and the clinical trial data behind them. A must-listen for any clinician caring for patients with rare lipid disorders, and a glimpse at a future where FCS management looks fundamentally different.
This episode's topic comes courtesy of Arrowhead Pharmaceuticals, Inc. a member of the NLA Industry Council.
Watch this episode on YouTube HERE.